Nanofiltration of single plasma donations

Feasibility study

T. Burnouf, M. Radosevich, M. El-Ekiaby, S. Satoh, T. Sato, S. N. Amin, G. F. Savidge, H. A. Goubran

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Background and Objectives Major technical developments have been made in recent years to improve the quality and safety of human plasma for transfusion and fractionation. The present study was performed to assess, for the first time, the feasibility of applying a nanofiltration process, using 75-nm and 35-nm mean pore size membranes (Planova® 75N and Planova® 35N), to human plasma. Materials and Methods Ten apheresis plasma units were obtained from 10 plasma donors. Within 4 h of collection, plasma was subjected to leucoreduction and filtration (using 75-nm and 35-nm mean pore size membranes) at 35 °C, at less than 1 bar pressure. Aliquots of plasma were taken at all steps of the filtration procedure and numerous plasma quality parameters were measured. In addition, six hepatitis C virus (HCV)-positive plasma donations were experimentally subjected to the same filtration sequence and subsequently assessed by RNA polymerase chain reaction (PCR) and branched-chain DNA-quantification assays. Results Leucoreduced plasma can be reproducibly nanofiltered onto a sequence of 75-nm and 35-nm membranes, at a flow rate of 450 ml/h and a temperature of 35 ± 0.5 °C. Some protein dilution, or loss, was found during filtration, but the plasma filtered through membranes with a mean pore size of 75 nm and 35 nm met in vitro specifications for use in transfusion or fractionation. There were no signs of activation of the coagulation system. HCV-positive plasma donations became negative, asjudged by PCR and branched-chain DNA assay results, after filtration through the 35-nm membrane. Conclusions It is possible to apply a 75 + 35-nm filtration process to leucoreduced human plasma. This technology may have important future benefits in improving the quality and safety of plasma, by removing blood cell debris and infectious agents.

Original languageEnglish
Pages (from-to)111-119
Number of pages9
JournalVox Sanguinis
Volume84
Issue number2
DOIs
Publication statusPublished - Feb 2003
Externally publishedYes

Fingerprint

Feasibility Studies
Membranes
Hepacivirus
Branched DNA Signal Amplification Assay
Safety
Polymerase Chain Reaction
Blood Component Removal
DNA-Directed RNA Polymerases
Protein C
Blood Cells

Keywords

  • Nanofiltration
  • Plasma
  • Proteins
  • Transfusion
  • TSE
  • Virus

ASJC Scopus subject areas

  • Hematology

Cite this

Burnouf, T., Radosevich, M., El-Ekiaby, M., Satoh, S., Sato, T., Amin, S. N., ... Goubran, H. A. (2003). Nanofiltration of single plasma donations: Feasibility study. Vox Sanguinis, 84(2), 111-119. https://doi.org/10.1046/j.1423-0410.2003.00265.x

Nanofiltration of single plasma donations : Feasibility study. / Burnouf, T.; Radosevich, M.; El-Ekiaby, M.; Satoh, S.; Sato, T.; Amin, S. N.; Savidge, G. F.; Goubran, H. A.

In: Vox Sanguinis, Vol. 84, No. 2, 02.2003, p. 111-119.

Research output: Contribution to journalArticle

Burnouf, T, Radosevich, M, El-Ekiaby, M, Satoh, S, Sato, T, Amin, SN, Savidge, GF & Goubran, HA 2003, 'Nanofiltration of single plasma donations: Feasibility study', Vox Sanguinis, vol. 84, no. 2, pp. 111-119. https://doi.org/10.1046/j.1423-0410.2003.00265.x
Burnouf T, Radosevich M, El-Ekiaby M, Satoh S, Sato T, Amin SN et al. Nanofiltration of single plasma donations: Feasibility study. Vox Sanguinis. 2003 Feb;84(2):111-119. https://doi.org/10.1046/j.1423-0410.2003.00265.x
Burnouf, T. ; Radosevich, M. ; El-Ekiaby, M. ; Satoh, S. ; Sato, T. ; Amin, S. N. ; Savidge, G. F. ; Goubran, H. A. / Nanofiltration of single plasma donations : Feasibility study. In: Vox Sanguinis. 2003 ; Vol. 84, No. 2. pp. 111-119.
@article{03395561565d4cdeb01bdad0f51ae338,
title = "Nanofiltration of single plasma donations: Feasibility study",
abstract = "Background and Objectives Major technical developments have been made in recent years to improve the quality and safety of human plasma for transfusion and fractionation. The present study was performed to assess, for the first time, the feasibility of applying a nanofiltration process, using 75-nm and 35-nm mean pore size membranes (Planova{\circledR} 75N and Planova{\circledR} 35N), to human plasma. Materials and Methods Ten apheresis plasma units were obtained from 10 plasma donors. Within 4 h of collection, plasma was subjected to leucoreduction and filtration (using 75-nm and 35-nm mean pore size membranes) at 35 °C, at less than 1 bar pressure. Aliquots of plasma were taken at all steps of the filtration procedure and numerous plasma quality parameters were measured. In addition, six hepatitis C virus (HCV)-positive plasma donations were experimentally subjected to the same filtration sequence and subsequently assessed by RNA polymerase chain reaction (PCR) and branched-chain DNA-quantification assays. Results Leucoreduced plasma can be reproducibly nanofiltered onto a sequence of 75-nm and 35-nm membranes, at a flow rate of 450 ml/h and a temperature of 35 ± 0.5 °C. Some protein dilution, or loss, was found during filtration, but the plasma filtered through membranes with a mean pore size of 75 nm and 35 nm met in vitro specifications for use in transfusion or fractionation. There were no signs of activation of the coagulation system. HCV-positive plasma donations became negative, asjudged by PCR and branched-chain DNA assay results, after filtration through the 35-nm membrane. Conclusions It is possible to apply a 75 + 35-nm filtration process to leucoreduced human plasma. This technology may have important future benefits in improving the quality and safety of plasma, by removing blood cell debris and infectious agents.",
keywords = "Nanofiltration, Plasma, Proteins, Transfusion, TSE, Virus",
author = "T. Burnouf and M. Radosevich and M. El-Ekiaby and S. Satoh and T. Sato and Amin, {S. N.} and Savidge, {G. F.} and Goubran, {H. A.}",
year = "2003",
month = "2",
doi = "10.1046/j.1423-0410.2003.00265.x",
language = "English",
volume = "84",
pages = "111--119",
journal = "Vox Sanguinis",
issn = "0042-9007",
publisher = "Blackwell Publishing Ltd",
number = "2",

}

TY - JOUR

T1 - Nanofiltration of single plasma donations

T2 - Feasibility study

AU - Burnouf, T.

AU - Radosevich, M.

AU - El-Ekiaby, M.

AU - Satoh, S.

AU - Sato, T.

AU - Amin, S. N.

AU - Savidge, G. F.

AU - Goubran, H. A.

PY - 2003/2

Y1 - 2003/2

N2 - Background and Objectives Major technical developments have been made in recent years to improve the quality and safety of human plasma for transfusion and fractionation. The present study was performed to assess, for the first time, the feasibility of applying a nanofiltration process, using 75-nm and 35-nm mean pore size membranes (Planova® 75N and Planova® 35N), to human plasma. Materials and Methods Ten apheresis plasma units were obtained from 10 plasma donors. Within 4 h of collection, plasma was subjected to leucoreduction and filtration (using 75-nm and 35-nm mean pore size membranes) at 35 °C, at less than 1 bar pressure. Aliquots of plasma were taken at all steps of the filtration procedure and numerous plasma quality parameters were measured. In addition, six hepatitis C virus (HCV)-positive plasma donations were experimentally subjected to the same filtration sequence and subsequently assessed by RNA polymerase chain reaction (PCR) and branched-chain DNA-quantification assays. Results Leucoreduced plasma can be reproducibly nanofiltered onto a sequence of 75-nm and 35-nm membranes, at a flow rate of 450 ml/h and a temperature of 35 ± 0.5 °C. Some protein dilution, or loss, was found during filtration, but the plasma filtered through membranes with a mean pore size of 75 nm and 35 nm met in vitro specifications for use in transfusion or fractionation. There were no signs of activation of the coagulation system. HCV-positive plasma donations became negative, asjudged by PCR and branched-chain DNA assay results, after filtration through the 35-nm membrane. Conclusions It is possible to apply a 75 + 35-nm filtration process to leucoreduced human plasma. This technology may have important future benefits in improving the quality and safety of plasma, by removing blood cell debris and infectious agents.

AB - Background and Objectives Major technical developments have been made in recent years to improve the quality and safety of human plasma for transfusion and fractionation. The present study was performed to assess, for the first time, the feasibility of applying a nanofiltration process, using 75-nm and 35-nm mean pore size membranes (Planova® 75N and Planova® 35N), to human plasma. Materials and Methods Ten apheresis plasma units were obtained from 10 plasma donors. Within 4 h of collection, plasma was subjected to leucoreduction and filtration (using 75-nm and 35-nm mean pore size membranes) at 35 °C, at less than 1 bar pressure. Aliquots of plasma were taken at all steps of the filtration procedure and numerous plasma quality parameters were measured. In addition, six hepatitis C virus (HCV)-positive plasma donations were experimentally subjected to the same filtration sequence and subsequently assessed by RNA polymerase chain reaction (PCR) and branched-chain DNA-quantification assays. Results Leucoreduced plasma can be reproducibly nanofiltered onto a sequence of 75-nm and 35-nm membranes, at a flow rate of 450 ml/h and a temperature of 35 ± 0.5 °C. Some protein dilution, or loss, was found during filtration, but the plasma filtered through membranes with a mean pore size of 75 nm and 35 nm met in vitro specifications for use in transfusion or fractionation. There were no signs of activation of the coagulation system. HCV-positive plasma donations became negative, asjudged by PCR and branched-chain DNA assay results, after filtration through the 35-nm membrane. Conclusions It is possible to apply a 75 + 35-nm filtration process to leucoreduced human plasma. This technology may have important future benefits in improving the quality and safety of plasma, by removing blood cell debris and infectious agents.

KW - Nanofiltration

KW - Plasma

KW - Proteins

KW - Transfusion

KW - TSE

KW - Virus

UR - http://www.scopus.com/inward/record.url?scp=0038666249&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038666249&partnerID=8YFLogxK

U2 - 10.1046/j.1423-0410.2003.00265.x

DO - 10.1046/j.1423-0410.2003.00265.x

M3 - Article

VL - 84

SP - 111

EP - 119

JO - Vox Sanguinis

JF - Vox Sanguinis

SN - 0042-9007

IS - 2

ER -